US Inhalation Systems Market Forecast up to 2024

  • 98
    Pages

  • 23
    Tables

  • 40
    Charts

  • 0 / 1
    Regions/ Countries

  • 14
    Companies

  • 10
    Enquiry Hours

Overview

The emergence of inhaled drug therapy has been a boon for patients with respiratory conditions such as COPD and asthma because of its painless and flexible administration when compared to injections. There are various kinds of inhalation systems available in the market, and these include inhalers and nebulizers. The two most commonly widespread respiratory diseases are asthma and COPD. According to WHO, around 235 million people are currently suffering from asthma, and it is very common in children. Chronic respiratory diseases such as asthma and COPD are responsible for substantial financial and health burden in the US, and in 2015, 6.7% deaths in the US were due to chronic respiratory diseases. Chronic obstructive pulmonary disease is the third leading cause of death across the globe, accounting for approximately 3 million deaths in 2016. State of West Virginia has the highest prevalence of COPD, and around 12% of the population are diagnosed with COPD.

The US inhalation systems market is driven by an upsurge in the prevalence of respiratory diseases, increasing geriatric population, and favorable reimbursement. However, side effects allied with the drug inhalation and unattainability of single effective inhaler device that can treat many disease conditions may slow down the growth of the market in the US.

Market Analysis – The “US Inhalation Systems Market” is estimated to witness a CAGR of 5.8% during the forecast period 2018–2024. The US market is analyzed based on three segments – products, applications, and end-users.

Product Analysis – The US inhalation systems market, by product, is segmented into inhalers and nebulizers. The market by inhalers type is further segmented into dry powder inhalers and metered dose inhalers. The market by nebulizers is segmented into ultrasonic nebulizer, pneumatic nebulizer, and mesh nebulizer. Inhalers occupied a major market share in 2017 and nebulizers segment is anticipated to grow at a high CAGR during the forecast period. The extensive usage of inhalers in the treatment of various respiratory illness such as asthma, chronic obstructive pulmonary disorder, and others makes the segment the major shareholder.

Application Analysis – The US inhalation systems market, by application, is segmented into asthma, chronic obstructive pulmonary disease (COPD), and others. Asthma occupied a major market share in 2017 and COPD is expected to grow at the highest rate in the next five years.

End-users Analysis – The US inhalation systems market by end-users is segmented into hospitals, ambulatory care centers, and home care centers. Hospitals occupied a major market share in 2017, and home care segment is expected to grow during the forecast period due to ease in the usage of modern products, less homecare cost, and the obtainability of reimbursement.

Key Players

Omron Corp., Boehringer Ingelheim GmbH, PARI GmbH, Philips Healthcare, Teleflex Incorporated, 3M, AptarGroup, Inc., Agilent Technologies, Inc., AstraZeneca PLC, Inspiro Medical Ltd., Teva Pharmaceutical Industries Ltd., Monaghan Medical Corporation, GlaxoSmithKline plc, Becton Dickinson and Company are few of the key players in the US inhalation systems market.

Competitive Analysis

There is an increase in approvals in recent years due to the popularity of the systems and also drug companies are launching new inhalation systems and collaborating with other vendors to develop innovative devices in the market. For instance, in February 2017, FDA approved two products developed by Teva Pharmaceutical Industries Ltd., ArmonAir RespiClick and AirDuo RespiClick, to treat adolescent and adult patients with asthma. In October 2017, FDA approved new inhalation device, named TD-300/A developed by United Therapeutics Corporation, for use with Tyvaso Inhalation Solution. The first triple combination inhaler named Trimbow launched for COPD in August 2017 and in February 2018, Teva Pharmaceutical Industries Ltd. announced the commercial availability of QVAR RediHaler Inhalation Aerosol to patients in the US.

Benefits – The report provides complete details about the products offered by inhalation system companies in various therapeutic verticals. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Key Stakeholders

1     Industry Outlook

1.1        Industry overview

1.2        Industry Trends

2     Report Outline 

2.1        Report Scope

2.2        Report Summary

2.3        Research Methodology

2.4        Report Assumptions

3     Market Snapshot

3.1        Market Definition – Infoholic Research

3.2        Advantages of inhalation systems

3.3        Limitations associated with inhalation systems

3.4        Segmented Addressable Market (SAM)

3.5        Trends of the US inhalation systems market

3.6        Related Markets

3.6.1     Sleep Apnea

3.6.2     Anesthesia

3.6.3     Pulmonary Medicine

4     Market Outlook 

4.1        History of Inhalation systems

4.2        Market segmentation

4.3        PEST Analysis

4.4        Porter 5(Five) Forces

5     Market Characteristics

5.1        DRO – US Inhalation Systems Market Dynamics

5.1.1     Drivers

5.1.1.1    Rising prevalence’s of respiratory diseases

5.1.1.2    Favorable reimbursement

5.1.1.3    Increasing geriatric population

5.1.2     Opportunities

5.1.2.1    Advancement in technology

5.1.2.2    Upsurge in the demand for home-care therapeutic devices

5.1.3     Restraints

5.1.3.1    Side effects allied with drug inhalation

5.1.3.2    Unattainability of solo effective inhaler device that can treat many disease conditions

5.2        DRO – Impact Analysis

5.3        Key Stakeholders

6     By Products: Market Size and Analysis

6.1        Overview

6.2        Inhalers

6.2.1     Dry powder inhalers

6.2.2     Metered dose inhaler

6.2.3     Soft mist inhaler

6.3        Nebulizers

6.3.1     Ultrasonic Nebulizers

6.3.2     Pneumatic/jet Nebulizers

6.3.3     Mesh Nebulizers

7     By Applications: Market Size and Analysis

7.1        Overview

7.2        Asthma

7.3        Chronic obstructive pulmonary disease (COPD)

7.4        Others

8     By End-Users: Market Size and Analysis

8.1        Overview

8.2        Hospitals

8.3        Ambulatory care centers

8.4        Home Care

9     Regions: Market Size and Analysis

9.1        Overview

9.2        United States

10   Competitive Landscape 

10.1     Overview

11   Vendor Profiles

11.1     Boehringer Ingelheim GmbH

11.1.1  Overview

11.1.2  Business Units

11.1.3  Geographic Presence

11.1.4  Business focus

11.1.5  SWOT analysis

11.1.6  Business Strategy

11.2     Omron Corp.

11.2.1  Overview

11.2.2  Business Units

11.2.3  Geographic Presence

11.2.4  Business Focus

11.2.5  SWOT Analysis

11.2.6  Business Strategies

11.3     PARI GmbH

11.3.1  Overview

11.3.2  Business Focus

11.3.3  SWOT Analysis

11.3.4  Business Strategies

11.4     Philips Healthcare

11.4.1  Overview

11.4.2  Business Units

11.4.3  Geographic Presence

11.4.4  Business Focus

11.4.5  SWOT Analysis

11.4.6  Business Strategy

11.5     3M

11.5.1  Overview

11.5.2  Business Units

11.5.3  Geographic Presence

11.5.4  Business Focus

11.5.5  SWOT Analysis

11.5.6  Business Strategy

12   Companies to Watch For

12.1     AptarGroup, Inc.

12.1.1  Overview

12.2     Teleflex Incorporated

12.2.1  Overview

12.3     Agilent Technologies

12.3.1  Overview

12.3.2  Agilent Technologies, Inc.: Recent Developments

12.4     Inspiro Medical Ltd. (a subsidiary of Opko Health, Inc.)

12.4.1  Overview

12.4.2  Inspiro Medical Ltd: Recent Developments

12.5     Monaghan Medical Corporation

12.5.1  Overview

12.5.2  Monaghan Medical Corporation: Recent Developments

12.6     Astra Zeneca PLC

12.6.1  Overview

12.6.2  AstraZeneca PLC: Recent Developments

12.7     GlaxoSmithKline plc

12.7.1  Overview

12.7.2  Glaxosmithkline Plc: Recent Developments

12.8     TEVA Pharmaceuticals Industries Ltd

12.8.1  Overview

12.8.2  TEVA Pharmaceuticals Industries LTD.: Recent Developments

12.9     Beckton Dickinson and Company

12.9.1  Overview

12.9.2  Beckton Dickinson and Company: Recent Developments

13   Annexure 

13.1        Abbreviations

Infoholic research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:

  • Data Collation (Primary & Secondary)
  • In-house Estimation (Based on proprietary data bases and Models)
  • Market Triangulation
  • Forecasting

infoholic Research Methodology

Market related information is congregated from both primary and secondary sources.

Primary sources involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.

Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.